EXtending the tIme Window of Thrombolysis by ButyphThalide up to 6 Hours After Onset (EXIT-BT)

NCT05189509 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Stroke, Ischemic

Interventions

DRUG: TNK-Tissue Plasminogen Activator

Sponsor

General Hospital of Shenyang Military Region